These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27503625)

  • 1. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature.
    Palmieri B; Poddighe D; Vadalà M; Laurino C; Carnovale C; Clementi E
    Immunol Res; 2017 Feb; 65(1):106-116. PubMed ID: 27503625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.
    Colafrancesco S; Perricone C; Tomljenovic L; Shoenfeld Y
    Am J Reprod Immunol; 2013 Oct; 70(4):309-16. PubMed ID: 23902317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.
    Herrin DM; Coates EE; Costner PJ; Kemp TJ; Nason MC; Saharia KK; Pan Y; Sarwar UN; Holman L; Yamshchikov G; Koup RA; Pang YY; Seder RA; Schiller JT; Graham BS; Pinto LA; Ledgerwood JE
    Hum Vaccin Immunother; 2014; 10(12):3446-54. PubMed ID: 25483691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus.
    Brinth LS; Pors K; Theibel AC; Mehlsen J
    Vaccine; 2015 May; 33(22):2602-5. PubMed ID: 25882168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothesis: Human papillomavirus vaccination syndrome--small fiber neuropathy and dysautonomia could be its underlying pathogenesis.
    Martínez-Lavín M
    Clin Rheumatol; 2015 Jul; 34(7):1165-9. PubMed ID: 25990003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatoform and neurocognitive syndromes after HPV immunization are not associated to cell-mediated hypersensitivity to aluminum.
    Poddighe D; Vadalà M; Laurino C; Palmieri B
    Toxicol In Vitro; 2017 Sep; 43():58-61. PubMed ID: 28599844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA).
    Hotta O; Tanaka A; Torigoe A; Imai K; Ieiri N;
    Immunol Res; 2017 Feb; 65(1):66-71. PubMed ID: 27592233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
    Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN
    Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems.
    Pellegrino P; Perrone V; Pozzi M; Carnovale C; Perrotta C; Clementi E; Radice S
    Immunol Res; 2015 Feb; 61(1-2):90-6. PubMed ID: 25381482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
    Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
    Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.
    Baker B; Eça Guimarães L; Tomljenovic L; Agmon-Levin N; Shoenfeld Y
    Expert Opin Drug Saf; 2015; 14(9):1387-94. PubMed ID: 26216756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.